Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bodi Envi vs Kin Meds

Bodi Envi
Graded #88

Lower grade

vs+1.1000000000000085
Kin Meds
Graded #73

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 71.8/100, but only just.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and… Bodi Envi is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +1
73
74
Dose & formulationKin Meds +21
72
93
Clinical oversightBodi Envi +8
82
74
Labs & monitoringBodi Envi +11
64
53
FulfillmentKin Meds +3
69
72
Contract termsBodi Envi +6
61
55
Bodi Envi · left barKin Meds · right bar

The numbers

MetricBodi EnviKin Meds
WeighScore71.8/10072.9/100
GradeCC
Scorecard rank#88#73
Semaglutide$179/mo$149/mo (brand Wegovy)
Tirzepatide$249/mo$149/mo (brand Zepbound)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Bodi Envi

Graded #88 · C

Strengths

  • Transparent flat pricing: compounded semaglutide $179/month and tirzepatide $249/month, all doses
  • No consultation or membership fees
  • Free 2-day shipping included; FSA and HSA eligible
  • 24/7 secure provider messaging with same-day visits and prescriptions
  • Personalized dose titration with side-effect management (Zofran available)

Where it loses points

  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • No insurance billing — cash-pay only
  • States served are not explicitly listed (features vary by state)
  • No LegitScript certification visible on the site
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard